Evotec and APEIRON Biologics start next project on the Cbl-b target

Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Press release Presseaussendung

October 20, 2011
View the Post